Interstitial CystitisMANAGEMENT

GENITOURINARY AND REPRODUCTIVE PRESENTATIONS · 12 SECTIONS

⚲

669 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Acute Kidney Injury (ATN)Acute Kidney Injury (Post-renal)Acute Kidney Injury (Pre-renal)Amniotic Fluid Embolism Balanitis Bladder Rupture Breast Abscess Cystitis Dialysis access complications Ectopic pregnancy Epididymitis Glomerulonephritis Hematuria (gross)Hydrocele Interstitial Cystitis Mastitis Mittelschmerz Nephrolithiasis Nephrotic Syndrome Flare Nutcracker Syndrome Orchitis Ovarian Cyst Rupture Ovarian hyperstimulation syndrome Ovarian torsion Paraphimosis Pelvic Congestion Syndrome Pelvic Inflammatory Disease (PID)Peritoneal dialysis peritonitis Phimosis Priapism Prostatitis Pyelonephritis Renal laceration Renal transplant complications and rejection Ruptured ovarian cyst Testicular torsion Torsion of Appendix Testis Tubo-ovarian abscess Ureteral Rupture Urethritis Urinary Retention Urinary tract infection (uncomplicated)Urolithiasis (renal colic)Vaginal bleeding (non-pregnant)Vaginitis (Bacterial)Vaginitis (Candidal)Varicocele Vulvovaginal Hematoma

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp32

Immediate priorities

›Critical presentations requiring urgent action

›Inability to void with severe suprapubic pain

›Acute urinary retention distinction from IC/BPS flare

›Bladder scan or catheterization to measure post-void residual

›Gross hematuria with clot retention

›Foley catheter irrigation for clot evacuation

›Urology consultation

›New neurological deficits (saddle anesthesia, leg weakness, bowel incontinence)

›Cauda equina syndrome exclusion required urgently

›Emergency MRI spine

Red flag recognition

›Alarm features distinguishing IC/BPS emergency from routine presentation

›Fever with dysuria — exclude complicated UTI or pyelonephritis

›Positive urine culture defines alternate diagnosis

›Blood cultures if systemic toxicity

›Rapid onset less than 6 weeks — less consistent with IC/BPS

›Consider acute infection, bladder stone, or foreign body

›Cystoscopy if bladder stone suspected

›Hematuria in older adults or smokers

›Bladder cancer workup required

›Urology referral within 2 weeks

›Intractable pain unresponsive to oral analgesia

›Brief ED observation with parenteral analgesia

›IV ketorolac 15-30 mg or IV morphine 0.1 mg/kg

Escalation triggers

›Conditions requiring specialist escalation

›Post-void residual greater than 100 mL

02History/hx77

Symptom characterization

›Core bladder pain syndrome features

›Suprapubic or pelvic pain, pressure, or discomfort

›Worsening with bladder filling

›Relief with voiding — hallmark feature

›Urinary frequency greater than 8 voids per day

›Small voided volumes per episode

›Nocturia (waking more than once per night)

›Urgency without urge incontinence

›Pain-driven urgency rather than detrusor overactivity

›Distinguishes from overactive bladder

Pain characteristics

›Pain location and quality

›Suprapubic pain (most common)

›Pelvic fullness or pressure sensation

›Burning or aching quality

›Urethral or perineal pain

›Dysuria without infection

›Ejaculatory pain in men

›Dyspareunia in women

›Pain during and after intercourse

›May worsen for days after sexual activity

Symptom triggers and flare patterns

›Common IC/BPS flare triggers (reported by approximately 90% of patients)

›Dietary triggers

›Caffeine, alcohol, carbonated beverages

›Citrus fruits, tomatoes, spicy foods

›Artificial sweeteners, vitamin C supplements

›Non-dietary triggers

›Psychological stress

›Sexual intercourse

›Menstruation

›Prolonged sitting, tight clothing, exercise

Duration and course

›Chronicity criteria

›Symptoms present for 6 weeks or longer required for diagnosis

›Acute onset less than 6 weeks suggests alternative etiology

›Relapsing-remitting course typical

›Symptom trajectory

›Gradual onset in majority

›Prodrome phenotype: onset in early 20s with systemic pain features

›Non-prodrome phenotype: onset in early 40s with bladder-centric symptoms

Associated symptoms and comorbidities

›Common comorbid conditions (nociplastic pain cluster)

›Irritable bowel syndrome (IBS) co-occurs in 30-75%

›Abdominal pain, bloating, diarrhea or constipation

›Shared central sensitization mechanism

›Fibromyalgia co-occurs in approximately 18%

›Diffuse myalgias, widespread pain

›Fatigue and sleep disturbance

›Chronic fatigue syndrome approximately 10%

›Post-exertional malaise

›Functional limitation

›Psychiatric comorbidities

›Depression and anxiety significantly more prevalent

›PTSD and adverse childhood experiences associated

Risk factors

›Patient-level risk factors

›Female sex (4:1 female-to-male ratio)

›Most prevalent in women aged 30-50

›Exogenous female hormones increase risk

›Autoimmune or rheumatologic conditions

›Rheumatoid arthritis, SLE, ankylosing spondylitis — higher odds

›History of recurrent UTIs with negative cultures

›May represent prodromal IC/BPS

›Childhood urological anomalies (hazard ratio 2.49)

›GI or psychiatric disorders in childhood also increase risk

Important negatives and red flags

›Features suggesting alternative diagnosis

›Hematuria (gross or microscopic) — mandates malignancy workup

›Especially in smokers, chemical exposure history, older adults

›Fever, pyuria, or positive urine culture — UTI rather than IC/BPS

›Symptoms onset under 6 weeks — acute infection, stone, or foreign body

›Post-void residual greater than 100 mL — outlet obstruction or neurogenic bladder

›Prior pelvic radiation or vaginal mesh — specialist referral required

Medication history

›Bladder-toxic medications

›Cyclophosphamide — hemorrhagic cystitis

›Urothelial injury distinct from IC/BPS

›Ketamine or ketamine analogue use

›Ketamine cystitis — severe refractory bladder dysfunction

›History of ketamine use must be elicited

›Prior pentosan polysulfate sodium use

›Duration and total cumulative dose important

›Pigmentary maculopathy risk with prolonged use

03Physical Exam/exam41

Vitals and general appearance

›Vital sign assessment

›Blood pressure and heart rate — typically normal in IC/BPS

›Abnormal vitals suggest alternative diagnosis

›Tachycardia may indicate pain severity or infection

›Temperature — fever indicates UTI, pyelonephritis, or abscess

›IC/BPS is afebrile by definition

›General pain assessment

›Pain severity score on 10-point VAS

›Functional limitation from pain

Abdominal and pelvic exam

›Abdominal examination

›Suprapubic tenderness on palpation

›Direct bladder tenderness over pubic symphysis

›Absence of peritoneal signs (no guarding or rebound)

›Flanks — costovertebral angle tenderness

›CVA tenderness suggests pyelonephritis not IC/BPS

›Pelvic examination in women

›Anterior vaginal wall palpation

›Bladder base tenderness — characteristic of IC/BPS

›Sensitivity for IC/BPS modest but clinically useful

›Levator ani and pelvic floor assessment

›Pelvic floor hypertonicity — tender trigger points

›Levator ani syndrome may coexist

›Vaginal atrophy signs (postmenopausal women)

›Genitourinary syndrome of menopause as IC/BPS mimic

›Pale, dry vaginal mucosa

04Differential Diagnosis/ddx42

Life-threatening diagnoses

›Must-not-miss diagnoses

›Bladder cancer (ICD-10 C67.9)

›Older patients, smokers, chemical exposure, hematuria

›CT urography and cystoscopy required

›Cauda equina syndrome (ICD-10 G83.4)

›Saddle anesthesia, leg weakness, bowel or bladder dysfunction

›Emergency MRI spine without delay

›Complicated UTI or urosepsis (ICD-10 N10, A41.51)

›Fever, CVA tenderness, positive culture

›IC/BPS diagnosis requires exclusion of active infection

Common mimics

›Conditions most frequently confused with IC/BPS

›Overactive bladder (OAB) (ICD-10 N32.81)

›Urgency and frequency WITHOUT pain — pain distinguishes IC/BPS

›IC/BPS misdiagnosed as OAB in up to 43% of cases

›Recurrent UTI (ICD-10 N30.00)

›Positive urine cultures — may coexist with IC/BPS

›Negative cultures favor IC/BPS diagnosis

›Endometriosis (ICD-10 N80.9)

›Cyclic pelvic pain, dysmenorrhea

›Co-occurs in approximately 48% of IC/BPS patients

›Vulvodynia (ICD-10 N94.810)

›Vulvar-localized pain rather than bladder-centric

›Often coexists with IC/BPS

›Pelvic floor myalgia / levator ani syndrome (ICD-10 M79.3)

›Trigger points on levator palpation

›Pain reproduced by digital examination

05Laboratory Tests/lt35

Urinalysis and urine culture

›First-line investigations

›Urinalysis with microscopy — required in all patients

›Must be negative for pyuria and bacteriuria to support IC/BPS

›Hematuria on UA requires malignancy workup regardless of IC/BPS diagnosis

›Urine culture — indicated in all patients

›Culture may be positive even with negative UA (false-negative dipstick)

›Negative culture is prerequisite for IC/BPS diagnosis

›Sensitivity of dipstick for UTI is only 75-96%

Urine cytology and special studies

›Malignancy screen

›Urine cytology — indicated when hematuria, smoking history, or older age

›Sensitivity for high-grade urothelial carcinoma approximately 84%

›Negative cytology does not exclude bladder cancer

›STI testing (gonorrhea and chlamydia NAAT)

›Indicated in sexually active patients with symptom overlap

›Urethritis may mimic IC/BPS

›PSA in men

›If prostatitis or malignancy suspected

Systemic labs

›When systemic illness suspected

›Complete blood count

›Leukocytosis supports infection not IC/BPS

›Anemia warrants malignancy consideration

›Basic metabolic panel

›Renal function for drug dosing (amitriptyline, gabapentinoids)

›Electrolytes if severe pain with poor intake

›ESR and CRP

06Diagnostic Tests/dt54

Scoring Systems

›IC/BPS validated symptom instruments

›Interstitial Cystitis Symptom Index (ICSI) — O'Leary-Sant scale

›4 items: urgency, frequency, nocturia, bladder pain

›Score 0-20; higher score indicates greater severity

›Validated for diagnosis support and treatment monitoring

›Interstitial Cystitis Problem Index (ICPI)

›4 items assessing impact on QOL

›Used alongside ICSI at each clinical visit

›Pelvic Pain and Urgency/Frequency (PUF) questionnaire

›8-item self-administered tool

›Score 10-14 warrants IC evaluation; greater than 15 highly suggestive

›Visual Analogue Scale (VAS) for pain

›0-10 pain score monitoring at each visit

›Serial documentation guides treatment escalation

MRI

›MRI role in IC/BPS

›MRI pelvis — not diagnostic for IC/BPS itself

›Role: exclusion of endometriosis, adenomyosis, pelvic masses

›Deep infiltrating endometriosis assessment

›MRI spine — indicated for neurological red flags

›Cauda equina exclusion in acute presentations

›Cord or nerve root compression identification

›MRI bladder

›Bladder wall thickening may be seen in IC/BPS but non-specific

›Superior soft tissue contrast for mass lesion characterization

›CT indications in IC/BPS workup

07Disposition/dispo36

Outpatient management

›Criteria for outpatient care (majority of IC/BPS presentations)

›Stable vitals with no evidence of infection or urinary retention

›Urine culture negative or pending with low suspicion for infection

›Post-void residual less than 100 mL

›Pain manageable with oral analgesics

›Initiate or adjust oral treatment plan

›Arrange urology or urogynecology follow-up within 4-6 weeks

Emergency department observation

›Indications for brief ED observation or short-stay admission

›Intractable pain unresponsive to oral regimen

›IV analgesia (ketorolac 15-30 mg or opioid bridging)

›Reassess pain within 2-4 hours

›Severe flare with inability to tolerate oral intake

›IV hydration and antiemetic support

›Oral medications resumed when tolerated

Admission criteria

›Inpatient admission indications (uncommon)

›Acute urinary retention requiring catheterization

›Urology consultation for management plan

›Suprapubic catheter consideration for prolonged retention

›Suspected surgical diagnosis (torsion, bowel obstruction, ectopic pregnancy)

›Alternative diagnosis driving admission decision

›Severe dehydration or electrolyte abnormality from pain-related poor intake

Specialist referral triggers

›Urology referral indications

›Hematuria (gross or microscopic) without UTI

›CT urography and cystoscopy within 2 weeks

08Treatment/t121

Behavioral and non-pharmacologic therapy (first-line)

›Behavioral modifications — recommended for all patients

›Dietary modification

›Systematic elimination diet to identify personal triggers

›Caffeine, alcohol, carbonated beverages, citrus, tomatoes, spicy foods

›Artificial sweeteners and vitamin C supplements to avoid

›Calcium glycerophosphate or sodium bicarbonate may reduce flare symptoms

›Bladder training

›Timed voiding to gradually extend intervals

›Relaxation techniques during urge episodes

›Fluid management

›Adjust intake to optimize urine concentration

›Avoid both concentrated and high-volume urine

›Stress management and psychological support

›Cognitive behavioral therapy (CBT) for pain catastrophizing

›Mindfulness-based stress reduction

›Support groups (Interstitial Cystitis Association)

Pelvic floor physical therapy

›Pelvic floor physiotherapy — recommended for patients with hypertonicity

›Manual therapy and myofascial release for trigger points

›12-week course typical initial trial

›Cochrane review supports benefit over global therapeutic massage

›Avoid Kegel exercises in patients with pelvic floor hypertonicity

›Strengthening exercises worsen symptoms in this subgroup

›AUA 2022 guideline recommendation

›Biofeedback training

›Relaxation of pelvic floor musculature

›Patient education on downtraining techniques

Oral pharmacotherapy

›Amitriptyline (tricyclic antidepressant)

›Amitriptyline 10-25 mg nightly — start low and titrate

›Target dose 25-75 mg nightly

›Mechanism: central pain modulation, bladder anticholinergic effect

›Evidence: significant symptom improvement in randomized trials

›Adverse effects: sedation, dry mouth, constipation, urinary retention risk

›Hydroxyzine (H1 antihistamine)

›Hydroxyzine 10-25 mg nightly — start low

›Target dose 25-75 mg nightly

›Benefit in patients with allergic history or mast cell hypothesis

›Adverse effects: sedation; minimal anticholinergic effect

›Cimetidine (H2 antagonist)

›Cimetidine 400 mg twice daily

›H2-receptor blockade mechanism in bladder mucosa

›Evidence from small RCT showing symptom improvement

›Well tolerated; check for drug interactions (CYP450 inhibitor)

›Gabapentinoids

›Gabapentin 100-300 mg three times daily — titrate to effect

›Target 1800-3600 mg/day in divided doses

›Renal dose adjustment required

›Adverse effects: sedation, dizziness, peripheral edema

›Pregabalin 75 mg twice daily — alternative

›Titrate to 150-300 mg twice daily

›Renal dose adjustment required

›Pentosan polysulfate sodium (PPS)

›Pentosan polysulfate 100 mg three times daily (300 mg/day total)

›Only FDA-approved oral therapy for IC/BPS

›Mechanism: glycosaminoglycan (GAG) layer restoration

›Conflicting efficacy data — Cochrane review shows modest benefit

›Response may take 3-6 months to observe

›Ophthalmologic monitoring required

›Baseline retinal exam before initiation

›Retinal exam within 6 months of initiation and annually thereafter

›Pigmentary maculopathy: dose-dependent, potentially irreversible

›Symptoms: difficulty reading, impaired dark adaptation, blurred vision

›Cumulative dose greater than 1500 g associated with higher maculopathy risk

›Analgesics for flare management

›NSAIDs (ibuprofen 400-600 mg three times daily with food)

›Short-term flare symptom relief

›Renal function monitoring with prolonged use

›Phenazopyridine 200 mg three times daily after meals

›Urinary analgesic — symptomatic relief only

›Maximum 2 days; urine orange discoloration expected

›Not to be used as diagnostic test for UTI

Intravesical instillations

›DMSO (dimethyl sulfoxide) intravesical instillation

›DMSO 50 mL of 50% solution instilled intravesically

›Dwell time 15-20 minutes, then voided

›Series of 6 treatments every 1-2 weeks

›Often combined with heparin, lidocaine, and steroid (DMSO cocktail)

›Characteristic garlic-like odor from skin during treatment

›Heparin intravesical

›Heparin 10,000-40,000 units in 10 mL sterile water

›Self-instillation daily or 3 times weekly

›GAG layer restoration mechanism

›Frequently combined with lidocaine for immediate relief

›Lidocaine intravesical

›Alkalinized lidocaine 2% 10-20 mL with sodium bicarbonate

›Dwell time 30-60 minutes

›Enhanced absorption with alkalinization (pH 8.0 target)

›Short-term pain relief; often combined with heparin

›Hyaluronic acid or chondroitin sulfate

›Hyaluronic acid 40 mg in 40 mL weekly for 4 weeks then monthly

›GAG layer augmentation; European approval; off-label in North America

›Chondroitin sulfate intravesical — evidence emerging

›Improved sexual function reported in IC/BPS patients in 2026 RCT

Procedures

›Cystoscopy with hydrodistension under anesthesia

›Distension to 80-100 cmH2O for 1-2 minutes

›Diagnostic and potentially therapeutic

›Symptomatic improvement in 30-50% short-term

›Effect typically lasts weeks to months; can be repeated

›Hunner lesion fulguration or resection

›Transurethral fulguration or laser ablation

›High responder rate (70-90%) in Hunner lesion subtype

›Lesion recurrence expected; repeat procedures often required

›Sacral neuromodulation

›InterStim device implantation

›Modulates S3 nerve root afferent signaling

›FDA-approved for urgency, frequency, and non-obstructive urinary retention

›Benefit demonstrated in refractory IC/BPS

›Two-stage procedure: test stimulation then permanent implant

›Botulinum toxin A intradetrusor injection

›OnabotulinumtoxinA 100-200 units in 20-40 injection sites

›Performed cystoscopically under sedation

›Mechanism: inhibition of sensory afferents and detrusor overactivity

›Effect duration 6-12 months; repeat injections required

›Risk of post-procedure urinary retention (up to 5-10%)

Major surgical options (refractory cases only)

›Surgical salvage for treatment-refractory IC/BPS

›Augmentation cystoplasty

›Bladder augmentation using bowel segment (typically ileum)

›Increases functional bladder capacity

›Significant surgical morbidity; life-long follow-up required

›Urinary diversion with or without cystectomy

›Considered only after all other options exhausted

›Ileal conduit or continent pouch

›Pain relief not guaranteed even after cystectomy

09Special Populations/sp65

Pregnancy

›IC/BPS in pregnancy

›Symptom course during pregnancy

›Variable — some patients improve, others worsen

›Increased bladder pressure from gravid uterus may worsen frequency

›Diagnostic considerations

›Exclude UTI rigorously — pregnancy increases risk

›Urine culture monthly if recurrent UTIs in history

›Hydronephrosis of pregnancy may coexist

›Safe treatment options in pregnancy

›Behavioral modifications: dietary changes, bladder training

›Pelvic floor physiotherapy — generally safe

›Intravesical heparin — considered low risk; limited systemic absorption

›Intravesical lidocaine — limited data; use cautiously

›Medications to avoid in pregnancy

›Amitriptyline — Category C; avoid in first trimester if possible

›Hydroxyzine — Category C; sedation and neonatal withdrawal risk

›Pentosan polysulfate sodium — Category B; avoid if possible

›Gabapentinoids — Category C; neonatal withdrawal reported

›NSAIDs — avoid after 20 weeks (fetal renal toxicity and premature ductus closure)

›DMSO — avoid; teratogenicity risk in animal models

›Multidisciplinary approach

›Co-management with maternal-fetal medicine specialist

›Urology or urogynecology input for refractory cases

Geriatric

›IC/BPS in older adults

›Diagnostic challenges

›Increased prevalence of other bladder conditions (OAB, prolapse, malignancy)

›IC/BPS often under-recognized in geriatric population

›Lower urinary tract symptoms overlap with benign prostatic hyperplasia in men

›Medication safety considerations

›Amitriptyline — high anticholinergic burden; Beers Criteria medication

›Increased fall risk, cognitive impairment, urinary retention

›Use lowest effective dose; consider alternatives

›Hydroxyzine — Beers Criteria; CNS effects in elderly

›Sedation and delirium risk

›Gabapentinoids — increased fall and sedation risk

›Start at lower doses (gabapentin 100 mg nightly)

›Renal dose adjustment essential as GFR declines with age

›NSAIDs — increased GI bleed and renal toxicity risk

›Avoid in patients with CKD, heart failure, or anticoagulation

›Preferred approaches in geriatric patients

›Emphasize behavioral modification as primary therapy

›Pelvic floor physiotherapy if physically able

›Cimetidine — relatively safe, minimal systemic side effects

›Intravesical instillations may be preferred over systemic agents

Pediatrics

›IC/BPS in children and adolescents

›Prevalence and presentation

›Rare in prepubertal children; more recognized in adolescents

›Symptoms similar to adults: pelvic pain, frequency, nocturia

›Childhood urological anomalies (hazard ratio 2.49) increase adult IC risk

›Diagnostic approach

›Pediatric pelvic pain workup includes exclusion of dysfunctional voiding

›Dysfunctional elimination syndrome commonly confused with IC in children

›Urine culture and voiding diary essential first steps

›Cystoscopy under general anesthesia considered in refractory cases

›Treatment in pediatric patients

›Behavioral therapy — first-line (dietary, bladder training)

›Pelvic floor physiotherapy with pediatric specialist

›Amitriptyline — limited pediatric IC data; off-label use

›Dose 0.3-1 mg/kg nightly (maximum 25 mg initially)

›Hydroxyzine — used for allergy-associated flares

›Gabapentin — off-label; start at low doses

›Intravesical instillations — generally reserved for adolescents refractory to oral therapy

›Psychosocial impact

›School attendance and social function affected

›Psychological support and family counseling essential

10Background/b71

Epidemiology

›Prevalence and incidence

›Prevalence in the United States: estimated 3-7% of women and 1-4% of men

›Up to 12 million Americans estimated to have IC/BPS

›Under-diagnosis is common — average diagnostic delay 3-7 years

›Female predominance: 4:1 female-to-male ratio

›Most common in women aged 30-50 years

›Prodrome phenotype onset in early 20s (systemic pain features)

›Non-prodrome phenotype onset in early 40s (bladder-centric)

›Misdiagnosis rate

›Up to 43% of IC/BPS cases initially misdiagnosed

›Most common misdiagnosis is OAB or recurrent UTI (Skove SL, 2019)

›Quality of life impact

›IC/BPS comparable to QOL impairment of end-stage renal disease

›Significant work productivity loss and sexual dysfunction

›Depression and anxiety substantially more prevalent

Pathophysiology

›Three recognized IC/BPS phenotypes with distinct pathophysiology

›Hunner lesion subtype (previously Type 1 or classic IC)

›Discrete inflammatory mucosal ulcers on cystoscopy

›Transmural lymphocytic and plasmacytic infiltration

›Urothelial denudation with subepithelial fibrosis

›Specific, targeted therapy (fulguration) highly effective

›Widespread pain / nociceptive subtype (previously non-ulcerative or Type 2)

›No Hunner lesions; diffuse bladder pain sensitization

›Central sensitization and neurogenic inflammation predominate

›Associated with systemic nociplastic pain syndrome cluster

›Low bladder capacity subtype

›Maximum anesthetic bladder capacity less than 400 mL

›Distinct functional impairment; may overlap with Hunner lesion type

›Urothelial barrier dysfunction

›Deficiency of glycosaminoglycan (GAG) protective mucus layer

›Increased urothelial permeability to urinary constituents

›Potassium intraluminal leakage activates sensory nerves

›APF (antiproliferative factor) secreted by urothelium impairs repair

›Mast cell activation

›Increased mast cell density in bladder submucosa and muscularis

›Histamine and cytokine release amplifies neurogenic inflammation

›Central sensitization

›Neuroplastic changes in spinal dorsal horn

›Windup and allodynia in pelvic visceral afferents

›Descending pain modulation impairment

›Shared neurogenic basis explains comorbid nociplastic pain conditions

›IBS, fibromyalgia, chronic fatigue, migraine, vulvodynia

›Immunological and autoimmune components

›T-lymphocyte and mast cell infiltration in bladder wall

›Elevated TNF-alpha, IL-6, IL-8 in bladder tissue

›Possible autoantibody role in subset of patients

Therapeutic Considerations

›2022 AUA/SUFU guideline framework

›No longer tiered treatment approach — treatment categories are individualized

›Behavioral and non-pharmacologic therapies — first-line for all patients

›Oral medications — second line, added to behavioral foundation

›Intravesical instillations — escalation for inadequate oral response

›Procedures — for refractory patients; Hunner lesion fulguration highest evidence

›Major surgery — only after all other options exhausted

›Phenotype-directed treatment emerging

›Hunner lesion subtype: cystoscopic fulguration preferred first

›Non-Hunner/nociceptive subtype: oral and intravesical pharmacotherapy

›Low bladder capacity: hydrodistension, augmentation surgery if refractory

›Evidence base limitations

›Most trials are small, lack sham controls, and have heterogeneous populations

›Cochrane 2020 network meta-analysis: intravesical treatment superior to oral

›Bayesian network meta-analysis 2021: combination intravesical cocktails most effective

›Placebo response rates of 20-40% complicate interpretation

›Cyclosporine A — reserved for refractory cases under specialist care

›Efficacy superior to pentosan polysulfate in direct comparison

›Significant adverse effect profile (nephrotoxicity, hypertension, infection)

›Requires monitoring of renal function and blood pressure

›Multimodal treatment strategy

›Best outcomes achieved with combination approaches

›Behavioral + pharmacologic therapy recommended simultaneously

›Pelvic floor physiotherapy added when hypertonicity present

›Psychological support integrated from diagnosis

11Patient Discharge Instructions/pdi33

copy discharge instructions

›Interstitial Cystitis / Bladder Pain Syndrome — Discharge Instructions

›What is interstitial cystitis (IC/BPS)?

›A chronic bladder condition causing pelvic pain, pressure, and urinary frequency

›Not caused by infection — your urine culture was negative

›A long-term condition with a relapsing-remitting course — complete cure is uncommon but symptoms can be well managed

›Medications prescribed

›Take all medications as directed; do not stop without discussing with your doctor

›If prescribed amitriptyline, take at bedtime — it may cause drowsiness

›If prescribed pentosan polysulfate (Elmiron), schedule a retinal eye exam within 6 months

›Dietary changes to try

›Avoid caffeine, alcohol, carbonated drinks, citrus, tomatoes, spicy foods

›Avoid artificial sweeteners and high-dose vitamin C

›Try one elimination at a time to identify your personal triggers

›Calcium glycerophosphate (Prelief) taken with meals may reduce flares

›Activity and lifestyle

›Avoid prolonged sitting without breaks

›Avoid tight clothing around the abdomen and pelvis

›Stress reduction techniques (mindfulness, yoga, CBT) can reduce flare frequency

›If pelvic floor physical therapy is recommended, attend all sessions — do NOT do Kegel exercises unless specifically instructed

›Follow-up appointments

›See your urologist or urogynecologist in 4-6 weeks for symptom reassessment

›Bring a completed 3-day voiding diary to your follow-up appointment

›If on pentosan polysulfate, arrange annual ophthalmology follow-up

›Return to the emergency department immediately if you develop

›Blood in your urine (red or dark brown urine)

›Fever greater than 38.3 degrees Celsius

›Complete inability to urinate

12References/r62

Guidelines and key sources

›AUA/SUFU Guideline 2022

›Clemens JQ, Erickson DR, Varela NP, Lai HH

›Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome

›The Journal of Urology 2022

›doi:10.1097/JU.0000000000002756

›Roepcke F, Jones AE, Falk KN

›Bladder Pain Syndrome: Rapid Evidence Review

›American Family Physician 2026

›PMID 42101600

›Joint terminology and international guidelines

›International Urogynecological Association and American Urogynecologic Society

›Joint Terminology Report: Terminology Standardization for Female Bladder Pain Syndrome

›International Urogynecology Journal 2025

›PMID 39751633

›ACOG Practice Bulletin Number 218 — Chronic Pelvic Pain

›Obstetrics and Gynecology 2020

›doi:10.1097/AOG.0000000000003716

›Systematic reviews and meta-analyses

›Imamura M et al

›Interventions for Treating People With Symptoms of Bladder Pain Syndrome: A Network Meta-Analysis

›Cochrane Database of Systematic Reviews 2020

›doi:10.1002/14651858.CD013325.pub2

›Di XP et al

›Efficacy and Safety Comparison of Pharmacotherapies for IC/BPS: Bayesian Network Meta-Analysis

›International Urogynecology Journal 2021

›PMID 33638677

›Epidemiology and comorbidity studies

Learn More: Interstitial Cystitis→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.